CV Therapeutics, Inc.
http://www.cvt.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CV Therapeutics, Inc.
J&J Acquires Heart Failure Implant Company V-Wave For Up To $1.7Bn, Expanding Its Medtech Portfolio In Cardiology
J&J buys heart failure implant company V-Wave, whose Ventura Interatrial Shunt could be the first device of its kind aimed to reach the roughly 800,000 patients in the US who experience heart failure and reduce ejection fraction every year.
Zydus Q1: Novel Molecule Enters Phase I, Global Biosimilar Strategy To Shift?
Zydus has begun Phase I trials for an anti-properdin drug in India while its sitagliptin franchise in US, distinct from Merck’s Januvia and Janumet, looks promising. Meanwhile MD Sharvil Patel says a biosimilars entry in developed markets is possible if certain conditions are met.
Caresyntax Secures $180M In Series C To Build Out AI-Enabled Surgical Software
Caresyntax said it will use the $180m it recently raised in a series C extension and debt financing round to build out its vendor-neutral surgery platform aimed to help surgeons with real-time and long-term decision support to improve patient outcomes and efficiencies.
Zydus Q1: Novel Molecule Enters Phase I, Global Biosimilar Strategy To Shift?
Zydus has begun Phase I trials for an anti-properdin drug in India while its sitagliptin franchise in US, distinct from Merck’s Januvia and Janumet, looks promising. Meanwhile MD Sharvil Patel says a biosimilars entry in developed markets is possible if certain conditions are met.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice